Related Experiment Video
Updated: Jul 10, 2026
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
[Update on thrombotic thrombocytopenic purpura]
N Schleinitz1, P Poullin, L Camoin
1Service de médecine interne, CHU La-Conception, AP-HM, Marseille cedex 5, France. nicolas.scleinitz@ap-hm.fr
La Revue De Medecine Interne
|November 21, 2007
Summary
Thrombotic thrombocytopenic purpura (TTP) is a serious condition requiring prompt treatment. Advances in understanding TTP pathophysiology and the use of rituximab offer new therapeutic options, challenging traditional plasma exchange methods.
Area of Science:
- Hematology
- Immunology
- Pathophysiology
Context:
- Thrombotic thrombocytopenic purpura (TTP) is a critical hematologic disorder.
- Understanding TTP pathophysiology is crucial for effective treatment.
- Acquired TTP is linked to inhibitory antibodies against ADAMTS-13.
Purpose:
- To review recent advances in TTP pathophysiology.
- To discuss novel therapeutic strategies for TTP.
- To highlight the role of rituximab in TTP treatment.
Summary:
- TTP results from deficiency of the ADAMTS-13 metalloprotease, which cleaves von Willebrand factor multimers.
- Inhibitory antibodies against ADAMTS-13 are associated with acquired TTP.
- Rituximab has shown promising results in refractory and relapsing TTP cases.
Impact:
- Improved characterization of TTP aids in selecting appropriate therapies.
- Rituximab represents a significant advancement in TTP treatment.
- New approaches, including rituximab, may challenge conventional plasma exchange therapy.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...